FMR LLC boosted its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 2.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,963,151 shares of the company's stock after acquiring an additional 327,498 shares during the period. FMR LLC owned 15.00% of IDEAYA Biosciences worth $333,153,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in IDYA. State Street Corp lifted its stake in IDEAYA Biosciences by 15.4% in the third quarter. State Street Corp now owns 3,317,936 shares of the company's stock valued at $105,112,000 after purchasing an additional 443,640 shares during the last quarter. Barclays PLC lifted its position in shares of IDEAYA Biosciences by 188.8% during the 3rd quarter. Barclays PLC now owns 181,170 shares of the company's stock valued at $5,739,000 after buying an additional 118,438 shares during the last quarter. Verition Fund Management LLC bought a new position in shares of IDEAYA Biosciences during the 3rd quarter worth $246,000. Geode Capital Management LLC increased its holdings in IDEAYA Biosciences by 9.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,945,455 shares of the company's stock worth $61,645,000 after acquiring an additional 172,838 shares during the last quarter. Finally, SG Americas Securities LLC raised its stake in IDEAYA Biosciences by 444.2% in the 4th quarter. SG Americas Securities LLC now owns 18,486 shares of the company's stock valued at $475,000 after acquiring an additional 15,089 shares during the period. 98.29% of the stock is currently owned by hedge funds and other institutional investors.
IDEAYA Biosciences Stock Down 4.0 %
Shares of IDYA stock traded down $0.68 during trading on Wednesday, hitting $16.31. The company had a trading volume of 363,643 shares, compared to its average volume of 1,080,570. IDEAYA Biosciences, Inc. has a 52 week low of $13.45 and a 52 week high of $44.42. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -4.94 and a beta of 0.51. The stock's 50-day moving average is $18.56 and its two-hundred day moving average is $24.11.
IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The firm had revenue of $7.00 million for the quarter, compared to analysts' expectations of $7.00 million. On average, research analysts predict that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.
Analyst Ratings Changes
IDYA has been the subject of several recent research reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Royal Bank of Canada reissued an "outperform" rating and set a $61.00 target price on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Stephens reaffirmed an "overweight" rating and issued a $50.00 price target on shares of IDEAYA Biosciences in a report on Friday, February 14th. Finally, Wedbush reiterated an "outperform" rating and set a $52.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, IDEAYA Biosciences presently has a consensus rating of "Moderate Buy" and an average target price of $53.58.
Get Our Latest Stock Report on IDYA
About IDEAYA Biosciences
(
Free Report)
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
Read More
Before you consider IDEAYA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEAYA Biosciences wasn't on the list.
While IDEAYA Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
